ABSTRACT
PURPOSE: To test the psychometric properties of the International Prostate Symptom Score (Hong Kong Chinese version 2) (IPSS) in Chinese male patients with benign prostatic hyperplasia (BPH) under secondary care. METHODS: A prospective longitudinal study was done by interviewing subjects at baseline, at 2 week after baseline for assessing test-retest reliability and at 26 week after baseline for assessing responsiveness. All subjects were interviewed to complete a structured questionnaire including IPSS, Short Form-12 Health Survey version 2 (SF-12v2) and Depression Anxiety Stress Scale (DASS). RESULTS: The IPSS HRQOL score had weak correlations with SF-12v2 summary and DASS domain scores. For reliability analysis, Cronbach's alpha coefficient was 0.90 for the seven symptom-related items. The intraclass correlation coefficients of the IPSS total symptom score and HRQOL score were 0.90 and 0.86, respectively. For sensitivity, statistically significant differences were detected between the subjects with BPH and those without for IPSS total symptom score (effect size = 0.68) but not the IPSS HRQOL score. The areas under ROC curves for the IPSS total symptom and HRQOL scores were 0.67 and 0.60, respectively. CONCLUSIONS: The IPSS was valid, reliable instrument in Chinese patients with BPH. The IPSS total symptom score, but not the HRQOL score, is sensitive in differentiating subgroups.
Subject(s)
Health Surveys , Prostatic Hyperplasia/psychology , Quality of Life , Aged , Anxiety/complications , Case-Control Studies , Depression/complications , Hong Kong , Humans , Longitudinal Studies , Male , Middle Aged , Prospective Studies , Prostatic Hyperplasia/complications , Prostatic Hyperplasia/physiopathology , Psychometrics , Reproducibility of Results , Stress, Psychological/complicationsABSTRACT
BACKGROUND: A prior study showed significant antibiotic resistance to quinolone in our population. In this study we aimed to evaluate and compare the efficacy of a single versus a combined prophylactic antibiotic regimen before transrectal ultrasound-guided prostate biopsy (TRUGPB). METHODS: A prospective randomized study was conducted at a university hospital. Patients undergoing TRUGPB were randomized into an amoxicillin-clavulanate alone (1 mg; one dose before and two doses after biopsy) or an amoxicillin-clavulanate + ciprofloxacin group (250 mg; one dose before and two doses after biopsy). Patients were surveyed for infection symptoms by phone on days 3 and 30 after TRUGPB. We defined an infective complication as the occurrence of symptoms including fever, chills or rigor within 30 days after prostate biopsy, requiring medical treatment or hospitalization, aided by a territory-wide electronic medical record system. RESULTS: Between November 2007 and July 2009, 367 patients were randomized to either amoxicillin-clavulanate alone or amoxicillin-clavulanate + ciprofloxacin group. The infection rates after TRUGPB were 3.91% in the former group (7 out of 179 patients) versus 0.53% (1 out of 188 patients) in the latter. Sixty-three percent (5/8) of patients with infective complications needed hospitalization. There was no intensive care unit admission or mortality during the study period. CONCLUSIONS: Combining prophylactic antibiotics with amoxicillin-clavulanate + ciprofloxacin significantly reduced the incidence of infective complications after TRUGPB. We recommended a combination regimen, especially in centre with high incidence of post-TRUGPB infection.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis/methods , Biopsy, Needle/adverse effects , Prostate/diagnostic imaging , Prostate/pathology , Rectum , Amoxicillin/therapeutic use , Biopsy, Needle/methods , Ciprofloxacin/therapeutic use , Clavulanic Acid/therapeutic use , Humans , Male , Prostate/surgery , UltrasonographyABSTRACT
UNLABELLED: We quantified the urine sediment and supernatant levels of microRNA (miRNA) targets related to epithelial-mesenchymal transition in 51 patients with bladder cancer and in 24 controls. We found that patients with bladder cancer had depressed levels of the miR-200 family, miR-192, and miR-155 in urinary sediment. The urinary level of these miRNAs may be developed as noninvasive markers for bladder cancer. BACKGROUND: MicroRNAs (miRNA) have been implicated to play an important role in the pathogenesis of a variety of cancers. We studied the levels of miRNAs related to epithelial-mesenchymal transition (EMT) in the urine of patients with bladder cancer. METHOD: The expression of the miR-200 family, miR-205, miR-192, miR-155, and miR-146a in the urine sediment and supernatant of 51 patients with bladder cancer and in 24 controls was determined by real-time quantitative polymerase chain reaction. RESULTS: Compared with controls, the patients with bladder cancer had a lower expression of the miR-200 family, miR-192, and miR-155 in the urinary sediment; lower expression of miR-192; and higher expression of miR-155 in the urinary supernatant. The expression of the miR-200 family, miR-205, and miR-192 in the urine sediment significantly correlated with urinary expression of EMT markers, including zinc finger E-box-binding homeobox 1, vimentin, transforming growth factor ß1, and Ras homolog gene family, member A. Furthermore, the levels of miR-200c and miR-141 in the urine sediment became normalized after surgery. CONCLUSION: We found that the urinary miR-200 family, miR-155, miR-192, and miR-205 levels are depressed in patients with bladder cancer. The level of these miRNA targets in urine has the potential to be developed as noninvasive markers for bladder cancer.
Subject(s)
Biomarkers, Tumor/urine , Carcinoma, Transitional Cell/urine , MicroRNAs/urine , Urinary Bladder Neoplasms/urine , Aged , Aged, 80 and over , Biomarkers, Tumor/genetics , Carcinoma, Transitional Cell/surgery , Case-Control Studies , Epithelial-Mesenchymal Transition , Female , Homeodomain Proteins/genetics , Homeodomain Proteins/urine , Humans , Male , MicroRNAs/genetics , Middle Aged , RNA, Messenger/genetics , RNA, Messenger/urine , Real-Time Polymerase Chain Reaction , Transcription Factors/genetics , Transcription Factors/urine , Transcription, Genetic , Transforming Growth Factor beta1/genetics , Transforming Growth Factor beta1/urine , Urinary Bladder Neoplasms/surgery , Vimentin/genetics , Vimentin/urine , Zinc Finger E-box-Binding Homeobox 1 , rhoA GTP-Binding Protein/genetics , rhoA GTP-Binding Protein/urineABSTRACT
UNLABELLED: Study Type - Diagnostic (exploratory cohort) Level of Evidence 3b What's known on the subject? and What does the study add? Electronic uroflowmetry reasonably predicts the likelihood of bladder outlet obstruction (BOO) and risk of AUR. This low-cost device, Uflowmeter(™) , allows men to perform uroflowmetry at home with ease and the results are compatible with that of electronic uroflowmentry. It can also estimates risk of AUR and the need for TURP to relieve LUTS. OBJECTIVE: To show the clinical value of a simple flowmeter, which has been devised to measure uroflow on an ordinal scale (<10, 10-15, 15-19 and >19 mL/s) at home, for the management of male lower urinary tract symptoms (LUTS). PATIENTS AND METHODS: A total of 186 men with LUTS were enrolled in the study. The mean (range) follow-up was 220 (68-431) days. The men's mean (range) age was 65.5 (46-83) years, mean (range) maximum urinary flow rate (Qmax) 12.8 (4.3-39.5) mL/s, mean (range) voided volume 294.8 (151-686) mL; mean (range) postvoid residual urine volume (PVR) 50 (0-303) mL and mean (range) International Prostate Symptom Score (IPSS) 13.5 (1-31). The men underwent electronic uroflowmetry ('clinic uroflowmetry') and completed an IPSS questionnaire in the clinic. They then conducted 10 measurements with the device at home ('home uroflowetry'). The uroflowmetry and IPSS questionnaire were repeated 2 weeks later. Quadratically weighted Kappa analysis (κ) of the home uroflowmetry vs. clinic uroflowmetry, and of the sensitivity and specificity of the home uroflowmetry values to correspond to the mean Qmax of clinic uroflowmetry (<10, 10-15, 15-19 and >19 mL/s) was performed. Similar analyses were performed for the IPSS. Kaplan-Meier analysis was performed to evaluate whether home uroflowmetry was able to prognosticate acute urinary retention (AUR) or the need for transurethral resection of the prostate (TURP). RESULTS: The home uroflowmetry values (κ= 0.84, 95% confidence interval [CI]: 0.78-0.90) were superior to the IPSS (κ= 0.083; 95% CI: 0-0.173) in correlating with the mean Qmax of clinic uroflowmetry. Home uroflowmetry was most sensitive in identifying a mean Qmax of >19 mL/s (sensitivity: 0.99; 95% CI:0.97-1.00) and most specific in identifying a mean Qmax of <10 mL/s (specificity: 0.90; 95% CI:0.83-0.94). The home uroflowmetry works best in ruling out a mean Qmax of <19 mL/s (diagnostic odds ratio [DOR]= 349.3; 95% CI:40.24-3037.7), followed by a mean Qmax of <15 mL/s (DOR = 91.02; 95% CI:31.23-265.23) and a mean Qmax of <10 mL/s (DOR = 32.04; 95% CI:14.0-73.19). Men with a home uroflowmetry value ≤10 mL/s were more likely (n= 6; 8.8%) than those with a home uroflowmetry value >10 mL/s (n= 2; 1.7%) to develop AUR or require TURP (log-rank test: P= 0.017; hazard ratio:5.61(95% CI:1.10-28.64)). The IPSS failed to display the same discriminative capability. CONCLUSION: Home uroflowmetry using this simple device is a satisfactory estimation of clinic uroflowmetry using an electronic flowmeter and can predict the significant progression of male LUTS.
Subject(s)
Flowmeters , Lower Urinary Tract Symptoms/diagnosis , Prostatic Hyperplasia/complications , Rheology/instrumentation , Self Care/instrumentation , Urinary Bladder Neck Obstruction/diagnosis , Aged , Aged, 80 and over , Cohort Studies , Equipment Design , Humans , Lower Urinary Tract Symptoms/etiology , Lower Urinary Tract Symptoms/therapy , Male , Middle Aged , Predictive Value of Tests , Prostatic Hyperplasia/physiopathology , Prostatic Hyperplasia/therapy , Urinary Bladder Neck Obstruction/etiology , Urinary Bladder Neck Obstruction/therapy , Urination/physiology , Urodynamics/physiologySubject(s)
Prostatectomy , Biopsy , Humans , Laparoscopy , Male , Prostate/pathology , Robotics , Time FactorsABSTRACT
OBJECTIVES: We report the natural history of voiding function in men with clinically localized prostate cancer after robot-assisted laparoscopic radical prostatectomy (RLRP), describing the trend of functional recovery, which is currently not well described using the robot-assisted laparoscopic approach. MATERIALS AND METHODS: We determined the impact on voiding function by prospectively evaluating 100 consecutive men who underwent RLRP between May 2005 and December 2006 and compared their reported International Prostate Symptom Score (IPSS) and Quality of Life (QOL) scores at 3, 6, and 12 months with preoperative scores after surgery. Patients with preoperative IPSS of 0-7 and 8-35 were defined as having mild lower urinary tract symptoms (LUTS) and moderate to severe LUTS, respectively. RESULTS: Continence was achieved in 82%, 87%, and 91% of men at 3, 6, and 12 months after RLRP, respectively. There were statistically and clinically significant improvements in both IPSS and QOL preoperative scores at all studied time points for patients with moderate to severe preexisting LUTS. The mean IPSS scores for these patients preoperatively and at 3, 6, and 12 months after surgery were 14.1, 5.2, 3.0, and 2.9, respectively and the corresponding mean QOL scores were 3.4, 2.1, 1.6, and 1.6, respectively. Patients with mild preexisting LUTS showed no statistically significant improvement in IPSS at 3 and 6 months after surgery but significant improvement was found at 1 year (P = 0.04). CONCLUSIONS: Good continence recovery is expected in most patients undergoing RLRP. Patients with moderate to severe preexisting LUTS can expect early and clinically significant symptom and QOL improvements after RLRP. Patients with mild preexisting LUTS show significant symptom improvement at 1 year.
Subject(s)
Prostatectomy/methods , Prostatic Neoplasms/physiopathology , Prostatic Neoplasms/surgery , Urination/physiology , Adult , Aged , Humans , Laparoscopy , Male , Middle Aged , Postoperative Period , Preoperative Period , Prospective Studies , Prostatectomy/instrumentation , Quality of Life , Robotics , Time Factors , Treatment OutcomeABSTRACT
PURPOSE: Studies among asymptomatic male subjects have suggested that a higher body mass index (BMI) is associated with lower serum prostate-specific antigen (PSA) levels. We aimed to investigate whether a similar effect also occurs in patients presenting with lower urinary tract symptoms (LUTS) to a urological unit and its potential implications. METHODS: A retrospective review was carried out at our centre between 2005 and 2009. The serum PSA and BMI of the patients were retrieved from a prospectively collected database. The BMI was divided into normal (< 23 kg/m2), overweight (23-27 kg/m2), and obese (>27 kg/m2) categories according to WHO recommendation for analysis of the association with PSA level. RESULTS: A total of 1,612 patients with a mean age of 64.6 were included. The mean PSA levels for the normal, overweight, and obese patients were 4.84, 4.54, and 3.95 ng/ml, respectively, with a significant negative correlation (Spearman's coefficient=-0.05, p=0.03). A significant negative association between PSA and BMI among the normal, overweight, and obese groups was also demonstrated by analysis of variance (p=0.01). After adjusting for age differences, there was a significant difference between PSA level for obese patients with a BMI>27 (3.95 ng/ml) and non-obese patients with a BMI<27 (4.67 ng/ml) with analysis of covariance (p=0.02). CONCLUSION: In symptomatic male patients, a higher BMI was significantly associated with lower PSA levels. BMI should be considered in the interpretation of serum PSA levels in overweight and obese patients presenting with LUTS.
Subject(s)
Body Mass Index , Lower Urinary Tract Symptoms/blood , Lower Urinary Tract Symptoms/physiopathology , Prostate-Specific Antigen/blood , Adult , Aged , Aged, 80 and over , Humans , Lower Urinary Tract Symptoms/complications , Male , Middle Aged , Obesity/blood , Obesity/complications , Obesity/physiopathology , Overweight/blood , Overweight/complications , Overweight/physiopathology , Prostatic Neoplasms/blood , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/physiopathology , Retrospective StudiesABSTRACT
OBJECTIVE: Live donor kidney transplantation is consistently superior to deceased donor kidney transplantation. Laparoscopic donor nephrectomy (LDN) is increasingly accepted as a safe and preferred surgical option. To evaluate the outcome of LDN and the impact of multiple arteries, a retrospective review was conducted on patients in two transplant centres. METHODS: Fifty patients including eight with double vessels were studied. Standard left transperitoneal LDN was performed. Grafts including those with double vessels were prepared using the bench technique. Postoperative outcomes (up to 1 year) for donors and recipients were studied. The outcomes of recipients of a single or double vessel graft were compared. RESULTS: All donors had an eventful recovery. No difference was found between the single and multiple vessels groups for operating time (168.21 ± 5.712 minutes vs. 197.50 ± 15.755 minutes) or hospital stay (3.21±0.165 days vs. 4.13±0.789 days). The recipient outcomes including hospital stay (10.17±0.596 days vs. 12.13 ± 1.797 days) and creatinine levels at day 7 (106.53 ± 5.583 µmol/L vs. 107.13 ± 11.857 µmol/L) and 1 year (120.21 ± 6.562 µmol/L vs. 124.75 ± 11.857 µmol/L) were similar. No ureteric stricture or graft loss was noted at 1-year follow-up. Recipient complications included lymphocoele (n = 2), haematoma (n = 3 with 2 requiring exploration), sepsis (n = 1), renal artery stenosis (n = 2 with 1 stented), repeated anastomosis (n = 1), and incisional hernia (n = 1). No differences were noted between the two groups. CONCLUSION: Our results showed that overall donor morbidity rate was low, as reflected by the short hospital stay. Also, the overall parameters of the recipients were good. In particular, no ureteric stricture was noted, and graft survival was 100% at 1 year. The outcomes of the reconstructed group, despite the technical challenge, were similar to those of the single-vessel group.
Subject(s)
Kidney Transplantation , Nephrectomy/methods , Renal Artery/abnormalities , Adult , Creatinine/blood , Female , Humans , Laparoscopy , Length of Stay , Male , Plastic Surgery ProceduresABSTRACT
Hepatocellular carcinoma (HCC) is an aggressive tumor with poor long-term prognosis. Here, we present an unusual patient with a solitary recurrence of HCC in the right kidney 12 years after the initial diagnosis. This illustrates the importance of considering late recurrence in patients with a history of HCC and the management of these metastases.
Subject(s)
Carcinoma, Hepatocellular/secondary , Liver Neoplasms , Retroperitoneal Neoplasms/secondary , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/surgery , Humans , Kidney Neoplasms/pathology , Kidney Neoplasms/secondary , Kidney Neoplasms/surgery , Male , Middle Aged , Retroperitoneal Neoplasms/pathology , Retroperitoneal Neoplasms/surgery , Time FactorsABSTRACT
BACKGROUND: Synovial sarcoma of the kidney is rare. It is clinicoradiologically indistinguishable from the more frequently encountered renal cell carcinoma. Histologically it needs to be differentiated from other spindle cell lesions occurring within the kidney, including a spectrum of benign to malignant tumors. Among malignant spindle cell tumors of the kidney, mimics of synovial sarcoma are sarcomatoid renal cell carcinoma, sarcomatoid urothelial carcinoma and other primary sarcomas, such as leiomyosarcoma and malignant fibrous histiocytoma. CASES: Four cases of synovial sarcoma originated in the kidney, with this report focusing on clinicopathologic and differential diagnostic features. CONCLUSION: The correct diagnosis of synovial sarcoma requires support by an immunohistochemical panel as well as adjunctive investigations like polymerase chain reaction and fluorescence in situ hybridization to determine the presence of the SYT-SSX fusion gene and translocation (X,18), respectively.
Subject(s)
Carcinoma, Renal Cell/pathology , Kidney Neoplasms/pathology , Sarcoma, Synovial/pathology , Adult , Carcinoma, Renal Cell/metabolism , Diagnosis, Differential , Female , Humans , Kidney Neoplasms/metabolism , Male , Oncogene Proteins, Fusion/metabolism , Sarcoma, Synovial/metabolismSubject(s)
Kidney Neoplasms/pathology , Neoplasms, Complex and Mixed/pathology , Aged , Female , Humans , Male , Middle Aged , Tomography, X-Ray ComputedABSTRACT
Bladder cancer is the ninth most common cancer in the world. Urothelial carcinoma (formerly known as transitional cell carcinoma) comprises the majority of bladder cancers. In order to decipher the genetic alteration leading to the carcinogenesis of urothelial cancer, we performed genome-wide allelotyping analysis using 384 microsatellite markers spanning 22 autosomes together with comparative genomic hybridization (CGH) in 21 urothelial cancer. High frequency of allelic imbalance was observed in chromosome arm 1q (61.9%), 3p (61.9%), 4q (66.67%), 8p (57.14%), 9p (76.2%) and 9q (66.67%). Allelic imbalance with frequency above average was also observed in chromosome arm 2q, 10p, 10q, 11p, 11q, 12q, 13q, 15q, 17p and 19q. The allelic imbalance of each case and fractional allelic loss for each chromosome was associated with higher tumor grade and stage (P<0.05). We have also delineated several minimal deletion regions on chromosome 3p, 4q, 8p, 9p, 9q, 11p, 13q, 16q and 17p. By CGH analysis, common chromosomal alterations included gain of 1p, 1q, 12q, 16p, 17q and 19p as well as loss of 4q and 9p in most of the cases. Our findings may provide valuable information to locate putative oncogenes and tumor suppressor genes in the carcinogenesis of bladder cancer in this locality.
Subject(s)
Allelic Imbalance , Comparative Genomic Hybridization/methods , Mutation , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/metabolism , Aged , Aged, 80 and over , Chromosome Deletion , Female , Gene Expression Profiling , Humans , Karyotyping , Loss of Heterozygosity , Male , Microsatellite Repeats , Middle AgedABSTRACT
AIMS: Prostate needle biopsy findings provide important information when considering treatment options. We examine the correlation between needle biopsy and radical prostatectomy pathology to predict patients at high risk of harbouring adverse pathological findings. METHODS: We reviewed data from 100 consecutive patients who underwent radical prostatectomy between 1 January 2003 and 31 January 2005 at the Singapore General Hospital. Pre-operative clinical findings and needle biopsy pathological data were prospectively collected and compared with the final histology. RESULTS: The mean pre-biopsy PSA level was 9.4 +/- 5.1 microg/L. Median maximum percent of tumour in any core was 50% (range 5-100) and mean percentage of positive cores was 34.5 +/- 23%. There was under-grading of the final tumour score in 27 (27%) patients on biopsy as compared with the radical prostatectomy, while over-grading occurred in eight (8%) patients. On stratifying patients pre-operatively into low risk and high risk groups, patients in the high risk group had a significantly higher chance of having adverse radical prostatectomy histology such as extraprostatic extension, positive surgical margins or tumour volume >3.0 mL (p = 0.041, OR = 3.96, 95%CI 1.13-13.86). CONCLUSIONS: Our results demonstrated good pathological correlation between prostate needle biopsies and their radical prostatectomies. Patients with Gleason scores of 7 or more, maximum percent of tumour in any core >50%, or percent of positive cores of >50% on needle biopsy had a higher risk of having adverse pathological findings at radical prostatectomy. The converse, however, is not necessarily true, as a result of sampling error during the biopsy.
Subject(s)
Biopsy, Needle , Prostatectomy , Prostatic Neoplasms/pathology , Prostatic Neoplasms/surgery , Aged , Humans , Male , Middle Aged , Prostate-Specific Antigen/blood , Reproducibility of ResultsABSTRACT
OBJECTIVE: To report the case of a man with an adrenal cavernous hemangioma presenting as a progressively enlarging adrenal mass with apparent hormonal hypersecretion. METHODS: We report the clinical, laboratory, imaging findings, and clinical course of this patient, and we highlight the important atypical features of this case. The literature is reviewed for the typical presentations of adrenal cavernous hemangiomas. RESULTS: A 59-year-old man presented with an adrenal incidentaloma that had an imaging phenotype suggestive of a pheochromocytoma or an adrenal carcinoma. The hormonal profile also suggested a state of aldosterone and catecholamine hypersecretion. Surgery, however, proved the diagnosis to be an adrenal cavernous hemangioma. CONCLUSION: Although adrenal cavernous hemangioma is a rare entity, it should be considered in the differential diagnosis of an adrenal incidentaloma. Its radiologic features are not specific, and the presence of hormonal hypersecretion does not exclude the diagnosis.
Subject(s)
Adrenal Gland Neoplasms/diagnosis , Adrenal Gland Neoplasms/metabolism , Hemangioma, Cavernous/diagnosis , Hemangioma, Cavernous/metabolism , Adrenal Gland Neoplasms/blood , Adrenal Gland Neoplasms/surgery , Aldosterone/blood , Aldosterone/metabolism , Disease Progression , Hemangioma, Cavernous/blood , Hemangioma, Cavernous/surgery , Humans , Hydrocortisone/blood , Hydrocortisone/metabolism , Hypertension/diagnosis , Hypertension/etiology , Incidental Findings , Male , Middle Aged , Renin/blood , Renin/metabolismABSTRACT
AIM: We assessed the team approach in reducing the learning curve during our 2-year experience transiting from open to robot-assisted laparoscopic radical prostatectomy (rLRP). METHODS: A team of three urologists progressed through assistant phase to console phase to obtain competency in robotic prostatectomy. One hundred patients underwent rLRP by this team using the da Vinci robotic surgical system from 1 February 2003 to 15 May 2005. RESULTS: The immediate perioperative outcome was divided into three corresponding time frames and the results demonstrated gradual improvement in outcome parameters. The mean set-up time and dissection time were 24+/-14 min and 182+/-52 min, respectively. The mean perioperative blood loss was 272+/-240 mL, and 7% of patients (n=7) required blood transfusion. The mean duration of bladder catheterization was 8.4+/-4.1 days, and mean hospital stay was 2.9+/-1.6 days. There was no perioperative mortality or conversion to open radical prostatectomy. Major complications (4%) included urethrovesical leak requiring re-operation, postoperative cerebrovascular accident, and transient ureteric obstruction. Minor complications (7%) included minor urethrovesical leak, bladder neck stenosis, and urinary tract infection. Mean follow up was 6.6+/-5.0 months. Pathological assessment showed pT2 disease in 55% and pT3 in 45% of specimens. CONCLUSIONS: A team-based approach to robot-assisted LRP helped to reduce the learning curve of the procedure for individual surgeons and continued to show significantly lower perioperative blood loss, transfusion requirements and postoperative pain compared to open radical retropubic prostatectomy.
Subject(s)
Group Processes , Laparoscopy , Professional Competence , Prostatectomy/education , Prostatic Diseases/surgery , Robotics/education , Follow-Up Studies , Humans , Laparoscopy/adverse effects , Male , Middle Aged , Prostatectomy/adverse effects , Prostatic Diseases/pathology , Robotics/trends , Treatment OutcomeABSTRACT
Contemporary medical robotic systems used in urologic surgery usually consist of a computer and a mechanical device to carry out the designated task with an image acquisition module. These systems are typically from one of the two categories: offline or online robots. Offline robots, also known as fixed path robots, are completely automated with pre-programmed motion planning based on pre-operative imaging studies where precise movements within set confines are carried out. Online robotic systems rely on continuous input from the surgeons and change their movements and actions according to the input in real time. This class of robots is further divided into endoscopic manipulators and master-slave robotic systems. Current robotic surgical systems have resulted in a paradigm shift in the minimally invasive approach to complex laparoscopic urological procedures. Future developments will focus on refining haptic feedback, system miniaturization and improved augmented reality and telesurgical capabilities.